Patent litigation enters a critical stage: According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), multiple patents of Catalyst Pharmaceuticals (NASDAQ: CPRX) core product Firdapse are facing court review.

These patents were originally set to expire in 2032, 2034, and 2037, but their validity is currently being challenged, and the case has entered a judge-only trial phase without a jury. Firdapse Market Exclusivity Under Scrutiny Firdapse is Catalyst's exclusive drug for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), and since its approval in 2018, it has remained the company's primary source of revenue. In 2023, the drug contributed over 180 millions USD in revenue, accounting for more than 90% of the company's total income. The patents under trial involve key formulation technologies and usage methods for Firdapse. If ruled invalid, the door to generic drug competition may open ahead of schedule. Patent Cliff Risk and Market Impact Typically, patent expiration leads to the entry of generics into the market, resulting in a significant decline in sales of the original drug. If the court rules these patents invalid, Firdapse's period of market exclusivity may be greatly shortened, posing a substantial threat to Catalyst's long-term revenue. Investors are closely monitoring the progress of the trial, as any unfavorable ruling could trigger stock price volatility. Industry Background and Regulatory Environment In recent years, U.S. courts have become increasingly strict in their review of pharmaceutical patents, with patent protections of several pharmaceutical companies being challenged. Meanwhile, the U.S. Food and Drug Administration (FDA) is actively promoting generic drug approvals to lower drug prices. This trend has made patent litigation a key factor affecting the valuation of pharmaceutical companies. Analyst Views and Market Expectations Wall Street analysts point out that the outcome of the patent litigation will have a profound impact on Catalyst's valuation. If the company successfully defends the validity of its patents, Firdapse's market exclusivity will extend to 2037, providing the company with stable cash flow. Conversely, if the patents are ruled invalid, the company may need to accelerate the development of new product pipelines to offset potential revenue losses.